Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) announces today that Susanna Helgesen and the Company have jointly decided to go their separate ways as there will be a change of the CFO role. Susanna will continue as CFO until a successor is appointed and a date for Susanna’s last day as CFO will be communicated once it has been decided. The Company has initiated a process to search for a replacement who will hold a combined CFO and IR role.

Susanna Helgesen has been CFO of Xbrane since May 2017.

"I want to thank Susanna for her strong efforts as CFO for Xbrane. She has been critical in our growth journey so far and especially in the process of getting on Nasdaq’s main list. I want to wish her all the best in her future career.”, says Martin Åmark, CEO.

Contacts

Martin Åmark, CEO/ IR 
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Attachments

Susanna Helgesen (CFO) leaves Xbrane

© Modular Finance, source Nordic Press Releases